Oncolytics Biotech Inc T.ONC

Biomarker driven trials in the era of precision medicine

[Noteable]

The benefits of this approach include the evaluation of a small number of patients per treatment, reduced costs, and rapid time to results and implementation across treatments and tumor types.

Patient enrollment in biomarker driven clinical trials is restricted to only biomarker-positive patients as ONCY is demonstrating with the Phase 2 Bracelet-1 breast cancer study where those patients who have been identified to respond to pelareorep + immune checkpoint inhibiton who have low levels of PD-1 were included in the trial.

[Noteable]

YES ... it would be more than prudent to ignore AprilWhine, as he prompted everyone to do.

[Noteable]

Precision oncology refers to the study of the tiny details of tumours to find genetic changes that can be targeted with treatments. Biomarkers are specific markers in the body that can help understand and treat the disease. Patients can be grouped based on how well they respond to treatments. This information can help doctors choose better treatments for patients and decide on who will benefit